Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | The impact of air pollution on disease characteristics and health disparities in AML

Anand Patel • 11 Sep 2024
SOHO 2024
Acute Myeloid Leukemia Leukemia

Anand Patel, MD, The University of Chicago Medicine, Chicago, IL, discusses how air pollutants, specifically PAHPOM, have been associated with an increased risk of acute myeloid leukemia (AML), especially in non-Hispanic black and Hispanic patients. Dr Patel believes that this information may enable hypothesis generation, and emphasizes that much more has to be learnt to properly understand the effects of pollution. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Anand Patel

Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs
2:40
Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs
Anand Patel • 25 Nov 2025
Phase Ib trial of ivosidenib plus ruxolitinib in IDH1-mutated advanced MPNs
2:05
Phase Ib trial of ivosidenib plus ruxolitinib in IDH1-mutated advanced MPNs
Anand Patel • 25 Nov 2025
Insights on menin inhibition and emerging strategies to improve response and MRD outcomes in AML
2:48
Insights on menin inhibition and emerging strategies to improve response and MRD outcomes in AML
Anand Patel • 25 Nov 2025
Primary efficacy analysis of TKI and inotuzumab ozogamicin-based therapy for newly diagnosed Ph+ ALL
4:18
Primary efficacy analysis of TKI and inotuzumab ozogamicin-based therapy for newly diagnosed Ph+ ALL
Anand Patel • 25 Nov 2025

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals